Selected ginsenosides interfere efficiently with hepatitis B virus mRNA expression levels and suppress viral surface antigen secretion

0562611 - BC 2023 RIV GB eng J - Journal Article
Duraisamy, G.S. - Jo, E. - Huvarová, I. - Park, K. H. - Heger, Z. - Adam, V. - Růžek, Daniel - Windisch, M.P. - Miller, A. D.
Selected ginsenosides interfere efficiently with hepatitis B virus mRNA expression levels and suppress viral surface antigen secretion.
Heliyon. Roč. 8, č. 9 (2022), č. článku e10465. ISSN 2405-8440. E-ISSN 2405-8440
Institutional support: RVO:60077344
Keywords : Ginsenoside * Hepatitis B virus * Lamivudine * Nucleoside/nucleotide analogues * Hepatitis B surface protein * Hepatitis B surface antigen * Chronic hepatitis B virus * Drug combinations
OECD category: Microbiology
Impact factor: 4, year: 2022
Method of publishing: Open access
https://www.sciencedirect.com/science/article/pii/S2405844022017534?via%3Dihub

Ginsenosides are a class of natural steroid glycosides and triterpene saponins found in Panax ginseng. After screening of a commercial ginsenoside compound library for low cellular cytotoxicity and the ability to mediate efficient reductions in hepatitis B virus (HBV) mRNA expression levels in HepG2.2.15 cells, three ginsenosides (Rg6, Rh4, and Rb3) are selected. Thereafter, using the same cellular model, all three ginsenosides are shown to mediate efficient, selective inhibition of HBV mRNA expression levels, and also interfere with the secretion of both HBV particles and hepatitis B surface antigen (HBsAg). Drug combination studies are performed in both HepG2.2.15 and HBV-infected HepG2-NTCPsec(+) cell models with the selected ginsenosides and lamivudine (LMV), a nucleoside analogue used to treat chronic hepatitis B (CHB) infections. These studies, involving RT-qPCR and ELISA, suggest that Rh4/LMV combinations in particular act synergistically to inhibit the secretion of HBV particles and HBsAg. Therefore, on the assumption that appropriate in vivo data are in future agreement, Rh4, in particular, might be used in combination with nucleoside/nucleotide analogues (NUCs) to devise an effective, cost-efficient combination therapy for the treatment of patients with CHB infections.
Permanent Link: https://hdl.handle.net/11104/0338676